229 results on '"Watts, N. B"'
Search Results
2. Self-perception of fracture risk: what can it tell us?
3. Adverse bone effects of medications used to treat non-skeletal disorders
4. Taxonomy of rare genetic metabolic bone disorders
5. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group
6. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study
7. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy
8. Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW)
9. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW)
10. Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women
11. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
12. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)
13. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK
14. The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design
15. Assessing response to osteoporosis therapy
16. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
17. Fracture risk remains reduced one year after discontinuation of risedronate
18. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
19. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
20. Combined Effects of Spaceflight and Age in Astronants as Assessed by Areal Bone Mineral Density and Trabecular Bone Score
21. The prevalence of significant left-right differences in hip bone mineral density
22. Risedronate for the Prevention and Treatment of Postmenopausal Osteoporosis: Results From Recent Clinical Trials
23. Treatment of Painful Osteoporotic Vertebral Fractures with Percutaneous Vertebroplasty or Kyphoplasty
24. Comparison of Bone and Total Alkaline Phosphatase and Bone Mineral Density in Postmenopausal Osteoporotic Women Treated with Alendronate
25. Clinical Use of Biochemical Markers of Bone Remodeling: Current Status and Future Directions
26. Combined Effects of Spaceflight and Age in Astronauts as Assessed by Areal Bone Mineral Density [BMD] and Trabecular Bone Score
27. “Evidence-based” or “logic-based” medicine?
28. Erratum to: Taxonomy of rare genetic metabolic bone disorders
29. Standards and Guidelines for Performing Central Dual X-Ray Densitometry from the Canadian Panel of International Society for Clinical Densitometry
30. Erratum to: Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy
31. Benign symmetric lipomatosis associated with protease inhibitors
32. A comprehensive fracture prevention strategy in older adults : The European union geriatric medicine society (EUGMS) statement
33. A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
34. Treatment with alendronate prevents fractures in women with postmenopausal osteoporosis
35. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women
36. Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women
37. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
38. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)
39. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK
40. Fracture risk remains reduced one year after discontinuation of risedronate
41. Assessment of non-vertebral fracture risk in postmenopausal women
42. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
43. What is osteopenia, and what should be done about it?
44. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis
45. Observational Data Do Not Establish Cause and Effect
46. Changing perceptions in osteoporosis
47. Endocrinology
48. Endocrinology
49. Four-Year Study of Intermittent Cyclic Etidronate Treatment of Postmenopausal Osteoporosis
50. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.